Background and Purpose-We tested whether blood-brain barrier dysfunction in subcortical white matter is associated with white matter abnormalities or risk of clinical dementia in older people (n=126; mean age 86.4, SD: 7.7 years) in the MRC CFAS (Medical Research Council Cognitive Function and Ageing Study). Methods-Using digital pathology, we quantified blood-brain barrier dysfunction (defined by immunohistochemical labeling for the plasma marker fibrinogen). This was assessed within subcortical white matter tissue samples harvested from postmortem T 2 magnetic resonance imaging (MRI)-detected white matter hyperintensities, from normal-appearing white matter (distant from coexistent MRI-defined hyperintensities), and from equivalent areas in MRI normal brains. Histopathologic lesions were defined using a marker for phagocytic microglia (CD68, clone PGM1 
D
iffuse white matter hyperintensities (WMHs) are frequently seen on T2-weighted and Fluid-attenuated inversion recovery magnetic resonance imaging (MRI) scans of older people. WMHs are associated with increased risk of lacunar stroke, vascular cognitive impairment, and Alzheimer's disease. 1 The blood-brain barrier (BBB) is a property of cerebral blood vessels, resulting from endothelial expression of tight junction proteins and molecular transporters. BBB dysfunction has been proposed as a cause of WMH, vascular cognitive impairment, and dementia. 2, 3 MRI data suggest that leakage of intravascular contrast agent, a marker of BBB dysfunction, is associated with WMH and vascular cognitive impairment. [4] [5] [6] [7] [8] Association of white matter pathology with BBB dysfunction inferred from detection of extravascular plasma proteins (such as fibrinogen, albumin, or IgG) is supported by some histological studies 9,10 though not others. 11, 12 We tested the hypotheses that BBB dysfunction (measured using fibrinogen labeling) is associated with risk of (1) white matter abnormalities (defined either by MRI or by histology) and (2) in-life dementia diagnosis. Throughout, we will maintain the distinction between radiologically defined WMH and histological white matter lesions (WMLs) defined on the basis of phagocytic microglia.
We used systematic MRI-guided tissue sampling in subcortical white matter from participants in a large population of donated human brains, the MRC CFAS (Medical Research Council Cognitive Function and Ageing Study) Neuropathology study.
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Materials and Methods

Human Tissue
The MRC CFAS Neuropathology study is a prospective longitudinal population-based study of cognitive impairment and frailty in the elderly. [13] [14] [15] Here, we sampled frontal and parietal subcortical white matter tissue blocks from donated brains. The 126 brains sampled represent all the donated brains from 3 (out of the 6) MRC CFAS centers, Newcastle, Nottingham and Cambridge, for which (1) formalin exposure was <10 years (median formalin time 5 years, range 3-7 years) and (2) luminal fibrinogen immunoreactivity was evident.
All cases reported (n=126) were over the age of 65 years (Table 1) . Postmortem tissue was obtained from subjects who signed a Declaration of Intent to donate their brain after death. This study had approval from the UK National Research Ethics Service.
Diagnosis of Dementia
Dementia status at death was determined from cognitive assessments during the last years of life (based on the full Geriatric Mental State AGECAT diagnostic algorithm, Methods in the online-only Data Supplement) combined with detailed retrospective interviews with a knowledgeable informant and death certificates. 13, 14, 16 Clinical dementia status was recorded in 116 participants. Among these, 69 (55%) had a clinical diagnosis of dementia during life (Table 1) .
Postmortem MRI Definition of WMH
MRI scans of fixed brain hemispheres were used to guide histological sampling of white matter tissue blocks, as detailed in previous reports. 15, 17 In brief, fixed hemispheres were cut into 10-mm-thick coronal slices (thick slices, Figure I in the online-only Data Supplement) for MRI. Scans were rated by consensus by 3 blinded observers using a modified Scheltens rating scale, as described previously (Methods in the online-only Data Supplement). 15, 17 WMHs were classified as deep subcortical or periventricular. In thick slices containing subcortical WMH, tissue blocks were cut from the thick slice to sample the MRI-defined WMH (these blocks inevitably also contained surrounding tissue; Figure I in the online-only Data Supplement). In addition, tissue blocks were cut from the same brain, from MRI WMH-free locations (normal-appearing white matter [NAWM]), after WMH blocks had been sampled. NAWM blocks were anatomically remote from WMH and from periventricular areas. Equivalent white matter areas were sampled from MRI normal control brains, in which no WMH had been detected. All blocks sampled were approximately 20×20×5 mm in size. All blocks were taken from deep subcortical white matter of frontal or parietal cortex, avoiding the corpus callosum and internal capsule. Periventricular WMH and periventricular white matter were avoided.
Histopathology and Immunohistochemical Labeling
Paraffin wax-embedded sections (6 µm thickness) were processed for immunohistochemistry as in our previous studies. 11 Primary antibodies were raised against human fibrinogen (rabbit polyclonal A-0080), 11 human IgG (rabbit polyclonal A-0423), 11 human CD68 (mouse monoclonal, clone PGM1), 15 and smooth muscle actin (mouse monoclonal, 1A4) all from Dako-Cytomation, Ely, United Kingdom; CD34 (mouse monoclonal, QBEnd10) and human IgG (mouse monoclonal, Clone RWP49) 11 were from Novocastra-Leica Microsystems, Newcastle-upon-Tyne, United Kingdom.
Definition of Histopathologic Lesions
CD68-labeled sections from all tissue blocks were viewed by a registered senior neuropathologist (L.R.B.) blind to MRI and clinical data. The CD68-PGM1 antibody is selective for phagocytic microglia and macrophages. CD68-positive cells, with amoeboid microglial morphology in clusters of greatest diameter at least 1.1 mm, were defined as histopathologic lesion (Figure 1A and 1B; Figure II in the online-only Data Supplement). This definition showed good interrater agreement when assessment of all sections was repeated by 2 independent, blinded cytopathologists (K.E., J.J.; Cohen κ=0.97).
Histological Image Analysis
All sections were digitally scanned under a 20× objective lens (Leica Slidescanner, UCL-Advanced Diagnostics, http://www.uclad.com/ digital_pathology/). Scanned sections in .SCN file format were viewed using Leica Slidepath Gateway free software (www.leicabiosystems.com/). Digital image analysis with National Institutes of Health ImageJ free software (http://imagej.nih.gov/ij) was used to estimate the extent (percent area fraction) of labeling with fibrinogen (Methods in the online-only Data Supplement; Figures II and III in the online-only Data Supplement).
Statistical Analysis
All histochemical labeling and image analyses were performed blind to clinical and MRI data. Sample size of 120 was estimated to detect a 20% difference in fibrinogen-labeled area fraction (α<0.05, β>0.8) based on previous studies using similar material.
11,17
Statistical analyses were performed using STATA, version 12. Analyses were performed by participant or by tissue block, as some participants had >1 brain region studied. As some participants contributed >1 tissue block, and each tissue block cannot be considered independent within the same brain, we used weighted analyses. All histological sections used to measure fibrinogen area fraction were used in the analyses and received a weight inversely proportional to the number of sections. For the comparison of categorical data, Fisher exact test was used as Cochran restrictions were present.
To test whether BBB dysfunction was a risk factor for MRI-defined WMH, we conducted weighted ordinal logistic regression analyses with WMH status as dependent variable (MRI normal, NAWM, WMH) and fibrinogen area fraction as independent variable. These analyses were repeated with histopathologically defined WML as dependent variable (none or present) and fibrinogen area fraction as independent variable. In addition, we conducted weighted linear regression analyses with MRI classification (MRI normal, NAWM, WMH) as independent variable and fibrinogen area fraction as dependent variable. The same analyses were repeated with histologically defined WML (none, present) as independent variable and also with combined MRI/histological methods (Table I in the online-only Data Supplement). In these analyses, control group (MRI normal or WML free) was set as the reference.
To test whether BBB dysfunction was a risk factor for dementia, we conducted weighted logistic regression analysis, with clinical dementia status (dementia, without dementia) as the dependent variable, and fibrinogen area fraction as independent variable.
All analyses were controlled for sex, age at death, and formalin time (time during which postmortem tissue was stored in formalin). All tests were 2-tailed, and P value <0.05 was considered significant.
Results
We report a sample of older people (n=126; mean age 86.4 (SD: 7.7) years; The mean extent of fibrinogen labeling was 1.03% (linearized SE 0.04%) across tissue blocks. There was no significant difference between tissue groups defined by MRI or histopathology in terms of fibrinogen area fraction (F(3, 648)=0.21; P=0.892). We tested whether BBB dysfunction was a risk factor for white matter abnormalities. Fibrinogen labeling was not significantly related to white matter abnormalities, either as MRI-defined WMH (odds ratio [OR], 0.90; 95% confidence interval [CI], 0.79-1.03; P=0.130) or as CD68-defined histological lesions (OR, 0.93; 95% CI, 0.77-1.12; P=0.452). According to linear regression analyses, the presence of a white matter abnormality identified either by MRI, histology, or combined methods was not significantly related to fibrinogen area fraction (Table I in the online-only Data Supplement).
We tested whether BBB dysfunction was associated with risk of clinical dementia. Across the cohort as a whole fibrinogen-labeled area fraction was not significantly associated with dementia status (OR, 0.93; 95% CI, 0.80-1.09; P=0.378). We repeated the analyses among MRI-defined subgroups and histology-defined subgroups (Table 2 ). Considering only participants who had no MRI-detected WMH, increased fibrinogen was significantly related to decreased risk of clinical dementia (OR, 0.74; 95% CI, 0.58-0.94; P=0.013; Table 2 ). Among participants where no CD68-defined WML was detected, fibrinogen was associated with decreased dementia risk (OR, 0.83; 95% CI, 0.70-0.98; P=0.032; Table 2 ). Among participants where at least 1 CD68-defined WML was detected (irrespective of MRI-defined tissue categories), a greater extent of fibrinogen labeling was related to increased risk of dementia (OR, 2.26; 95% CI, 1.25-4.08; P=0.007; Table 2 ). 
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Discussion
Fibrinogen immunolabeling of parenchymal cells and tissue was a frequent finding in this population-based study of older persons. We have interpreted this as indicative of BBB dysfunction, although clearly the degree of labeling is also dependent on tissue clearance pathways and cellular uptake and metabolism. In common with prior neuropathology studies, 10, 11, 18, 19 we routinely observed cellular and axonal labeling, suggesting an active uptake process. The concept that some degree of BBB permeability is common in older people is supported by extravasation of contrast agent in MRI studies [4] [5] [6] [7] [8] 20 and biochemical detection of plasma markers in cerebrospinal fluid. 5, 20, 21 The concept is further supported by observations that brain amyloid can be depleted by systemic immunotherapy, 22 implying BBB penetration by circulating antibodies. Elevated BBB permeability may occur transiently, possibly in a regional mosaic, becoming more common with increasing age. 23, 24 Recent studies in experimental mice suggest that the healthy BBB exhibits some (small) degree of permeability to most solutes, across a wide range of molecular size (molecular weight 86-150 000). 25, 26 Efflux may be via defective tight junctions or alternatively may be via a transcellular pathway. 27 In our data, BBB dysfunction in brains harboring histologically defined WMLs was associated with greater risk of clinical dementia. This finding may be explained by toxic effects of plasma-derived fluid within areas of tissue damage (where transmembrane ionic gradients and transport pathways are likely to be disrupted). Our data agree with previous neuropathology cohort studies where markers of plasma extravasation were positively associated with dementia diagnosis 10, 11, 18 or specifically with Alzheimer's disease. 3, 19, 28, 29 Experiments in animals demonstrate cytotoxic effects of plasma-derived molecules such as fibrinogen on axons, myelin, and other white matter components. 30, 31 Taken together, these findings suggest that BBB dysfunction may exacerbate the cognitive impact of active WMLs. 1 On post hoc subgroup analysis, we found a significant negative association of BBB dysfunction with dementia risk among participants without detectable WMH (MRI normal brains, Table 2 ). This finding was at borderline significance (P=0.013) and may represent a false positive, because of multiple hypothesis testing. If correct, a negative association implies a possible preconditioning action of plasma extravasation. Brain tissue expresses a complex array of molecular mechanisms for degradation and clearance of parenchymal debris. 24 We speculate that in older persons without WMH, these clearance pathways may be augmented by modest plasma-derived fluid efflux.
Contrary to our hypothesis, the extent of fibrinogen labeling was not a risk factor for white matter abnormalities. Fibrinogen labeling within blocks cut from WMH, or within blocks containing CD68-defined histological lesions, did not significantly differ from other tissue types. Thus, our data do To test blood-brain barrier dysfunction as a risk factor for dementia, we conducted weighted logistic regression analysis, with clinical dementia status (dementia, without dementia) as dependent variable and fibrinogen area fraction as independent variable. P<0.05 considered significant. CI indicates confidence interval; MRI, magnetic resonance imaging; NAWM, normal-appearing white matter; OR, odds ratio; and WMH, white matter hyperintensity. FGEN, D) . Capillaries are evident in the CD34-labeled section (arrows, B) and not in the SMA-labeled section. In D, fibrinogen labeling is evident around the small artery in cells and in axons (arrowheads). In this example, enhanced perivascular fibrinogen labeling is not seen around capillaries (arrows). Scale bars 100 µm.
not support the hypothesis that BBB dysfunction is associated with WMH or with WMLs. This contrasts with previous neuropathology studies in small cohorts. 9, 10 Unlike the present study, these were not targeted to subcortical white matter. In accord with the present findings, previous well-powered neuropathology studies found no relation of histological BBB markers with WMH. 11, 12 These findings resemble those in white matter of multiple sclerosis patients, where clusters of activated microglia were not significantly associated with heightened BBB dysfunction. 32 Our data conflict with some previous MRI studies, where enhanced contrast agent extravasation was seen in patients with cerebrovascular disease. [4] [5] [6] [7] [8] Size-selective changes in BBB permeability may reconcile neuropathology data from our study and others 11, 12 with these MRI findings. Size-selective BBB opening is observed in experimental mice subjected to chronic systemic treatment with low-dose angiotensin II, 26 or where the tight junction protein claudin-5 was genetically deleted. 33 In the brains of these mice, efflux of water and small solutes (including MRI contrast agents, molecular weight<1000) was evident, whereas large plasma protein molecules were retained. 11, 26, 33 Extravasation of small solutes may be associated with WMH, whereas larger solutes (including proteins such as fibrinogen) are not.
The present study has several limitations. First, MRI scans were performed postmortem with low-field strength (1.0 T). Nevertheless, recent quantitative comparisons show reasonable correlation of postmortem T2-weighted images with antemortem MRI. 34 Second, we report on just one, late-stage time point for each participant. By the nature of a neuropathology study, we lack information on the longitudinal development of tissue lesions. Third, the post hoc analyses of fibrinogen data raise the possibility of false-positive associations and should be viewed with caution. In addition, we did not include potential confounding covariates (such as APOE genotype).
Conclusions
Our data confirm that some degree of BBB dysfunction is common in older people. For the histological marker of BBB dysfunction that we used, we detected post hoc significant associations with dementia risk. No direct association with white matter changes was detected. If confirmed, these data raise the possibility that BBB dysfunction may be an independent marker for clinical dementia risk, additional to standard MRI biomarkers.
